Treatment options in relapsed CLL
| Outcome . | Ibrutinib1 (n = 195) . | Bendamustine plus rituximab3 (n = 78) . | Fludarabine plus cyclophosphamide plus rituximab4 (n = 276) . | Idelalisib/ Rituximab5 (n = 110) . | Venetoclax/ rituximab10 (n = 194) . |
|---|---|---|---|---|---|
| ORR, % | 91 | 59 | 70 | 81 | 93 |
| CR, % | 9 | 9 | 24 | 0 | 27 |
| Median progression-free survival, mo | n.r. (at mo 36, 59% were progression free) | 15.2 | 30.6 | n.r. (at mo 6, 93% were progression free) | n.r. (at mo 24, 85% were progression free) |
| Median overall survival, mo | n.r. (at mo 36, 74% were alive) | 33.9 | n.r. (at mo 25, >90% were alive) | n.r. (at mo 12, 92% were alive) | n.r. (at mo 24, 92% were alive) |
| Outcome . | Ibrutinib1 (n = 195) . | Bendamustine plus rituximab3 (n = 78) . | Fludarabine plus cyclophosphamide plus rituximab4 (n = 276) . | Idelalisib/ Rituximab5 (n = 110) . | Venetoclax/ rituximab10 (n = 194) . |
|---|---|---|---|---|---|
| ORR, % | 91 | 59 | 70 | 81 | 93 |
| CR, % | 9 | 9 | 24 | 0 | 27 |
| Median progression-free survival, mo | n.r. (at mo 36, 59% were progression free) | 15.2 | 30.6 | n.r. (at mo 6, 93% were progression free) | n.r. (at mo 24, 85% were progression free) |
| Median overall survival, mo | n.r. (at mo 36, 74% were alive) | 33.9 | n.r. (at mo 25, >90% were alive) | n.r. (at mo 12, 92% were alive) | n.r. (at mo 24, 92% were alive) |
CR, complete remission; n.r., not reached; ORR, overall response rate.